{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:51:32Z","timestamp":1782964292980,"version":"3.54.5"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000},"content-version":"vor","delay-in-days":53,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR062522"],"award-info":[{"award-number":["R01AR062522"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30AR069620"],"award-info":[{"award-number":["P30AR069620"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Osteogenesis imperfecta (OI) is a genetic disorder characterized by altered bone quality and imbalanced bone remodeling, leading to skeletal fractures that are most prominent during childhood. Treatments for OI have focused on restoring pediatric bone density and architecture to recover functional strength and consequently reduce fragility. Though antiresorptive agents like bisphosphonates (BPs) are currently the most common intervention for the treatment of OI, a number of studies have shown efficacy of sclerostin antibody (SclAb) in inducing gains in bone mass and reducing fragility in OI mouse models. In this study, the effects of the concurrent use of BP and SclAb were evaluated during bone growth in a mouse harboring an OI-causing Gly\u2192Cys mutation on col1a1. A single dose of antiresorptive BP facilitated the anabolic action of SclAb by increasing availability of surfaces for new bone formation via retention of primary trabeculae that would otherwise be remodeled. Chronic effects of concurrent administration of BP and SclAb revealed that accumulating cycles conferred synergistic gains in trabecular mass and vertebral stiffness, suggesting a distinct advantage of both therapies combined. Cortical gains in mass and strength occurred through SclAb alone, independent of presence of BP. In conclusion, these preclinical results support the scientific hypothesis that minimal antiresorptive treatment can amplify the effects of SclAb during early stages of skeletal growth to further improve bone structure and rigidity, a beneficial outcome for children with OI. \u00a9 2018 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.3421","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T19:32:48Z","timestamp":1521142368000},"page":"1272-1282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl\/+ Osteogenesis Imperfecta Mouse Model"],"prefix":"10.1093","volume":"33","author":[{"given":"Diana","family":"Olvera","sequence":"first","affiliation":[{"name":"Department of Biomedical EngineeringUniversity of MichiganAnn ArborMIUSA"},{"name":"Department of Orthopaedic SurgeryUniversity of MichiganAnn ArborMIUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Stolzenfeld","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic SurgeryUniversity of MichiganAnn ArborMIUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan C","family":"Marini","sequence":"additional","affiliation":[{"name":"Bone and Extracellular Matrix BranchNational Institute of Child Health and Human DisordersNational Institutes of HealthBethesdaMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S","family":"Caird","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic SurgeryUniversity of MichiganAnn ArborMIUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M","family":"Kozloff","sequence":"additional","affiliation":[{"name":"Department of Biomedical EngineeringUniversity of MichiganAnn ArborMIUSA"},{"name":"Department of Orthopaedic SurgeryUniversity of MichiganAnn ArborMIUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"issue":"10028","key":"2024021014324990900_jbmr3421-bib-0001","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"issue":"9418","key":"2024021014324990900_jbmr3421-bib-0002","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"2024021014324990900_jbmr3421-bib-0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.22203\/eCM.v005a04","article-title":"Osteogenesis imperfecta\u2014clinical and molecular diversity","volume":"5","author":"Roughley","year":"2003","journal-title":"Eur Cell Mater"},{"issue":"Suppl 2","key":"2024021014324990900_jbmr3421-bib-0004","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024021014324990900_jbmr3421-bib-0005","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"issue":"1","key":"2024021014324990900_jbmr3421-bib-0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","article-title":"Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review","volume":"51","author":"Castillo","year":"2009","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"2024021014324990900_jbmr3421-bib-0007","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1-2","key":"2024021014324990900_jbmr3421-bib-0008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/JPEM.2010.23.1-2.73","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta","volume":"23","author":"Salehpour","year":"2010","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"2024021014324990900_jbmr3421-bib-0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","article-title":"A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta","volume":"25","author":"Bishop","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"9902","key":"2024021014324990900_jbmr3421-bib-0010","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"2024021014324990900_jbmr3421-bib-0011","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00223-015-0061-y","article-title":"Evaluation of a modified pamidronate protocol for the treatment of osteogenesis imperfecta","volume":"98","author":"Palomo","year":"2016","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2024021014324990900_jbmr3421-bib-0012","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2024021014324990900_jbmr3421-bib-0013","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1210\/en.2013-1993","article-title":"Effect of bisphosphonates on the rapidly growing male murine skeleton","volume":"155","author":"Zhu","year":"2014","journal-title":"Endocrinology"},{"issue":"4","key":"2024021014324990900_jbmr3421-bib-0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.59566\/IJBS.2009.5345","article-title":"Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta","volume":"5","author":"Evans","year":"2009","journal-title":"Int J Biomed Sci"},{"issue":"16","key":"2024021014324990900_jbmr3421-bib-0015","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.jbiomech.2008.09.028","article-title":"Bisphosphonate treatment in the oim mouse model alters bone modeling during growth","volume":"41","author":"Rao","year":"2008","journal-title":"J Biomech"},{"issue":"5","key":"2024021014324990900_jbmr3421-bib-0016","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model","volume":"52","author":"McCarthy","year":"2002","journal-title":"Pediatr Res"},{"issue":"5","key":"2024021014324990900_jbmr3421-bib-0017","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024021014324990900_jbmr3421-bib-0018","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024021014324990900_jbmr3421-bib-0019","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos Int"},{"key":"2024021014324990900_jbmr3421-bib-0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"2024021014324990900_jbmr3421-bib-0021","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"issue":"1","key":"2024021014324990900_jbmr3421-bib-0022","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2024021014324990900_jbmr3421-bib-0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bone.2016.09.013","article-title":"Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+ osteogenesis imperfecta model","volume":"93","author":"Perosky","year":"2016","journal-title":"Bone"},{"issue":"7","key":"2024021014324990900_jbmr3421-bib-0024","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"13","key":"2024021014324990900_jbmr3421-bib-0025","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"issue":"53","key":"2024021014324990900_jbmr3421-bib-0026","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.1074\/jbc.274.53.37923","article-title":"Use of the Cre\/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice","volume":"274","author":"Forlino","year":"1999","journal-title":"J Biol Chem"},{"issue":"6","key":"2024021014324990900_jbmr3421-bib-0027","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bone.2009.07.078","article-title":"Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD","volume":"45","author":"Meganck","year":"2009","journal-title":"Bone"},{"issue":"14","key":"2024021014324990900_jbmr3421-bib-0028","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"issue":"8","key":"2024021014324990900_jbmr3421-bib-0029","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jbmr.66","article-title":"Near-infrared fluorescent probe traces bisphosphonate delivery and retention in vivo","volume":"25","author":"Kozloff","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014324990900_jbmr3421-bib-0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"9","author":"Otsu","year":"1979","journal-title":"IEEE Trans Syst Man Cybern"},{"issue":"2)","key":"2024021014324990900_jbmr3421-bib-0031","first-page":"RJ01","article-title":"Zebra stripe\u201d sign and \u201cbone in bone\u201d sign in cyclical bisphosphonate therapy","volume":"11","author":"Chakraborty","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"8","key":"2024021014324990900_jbmr3421-bib-0032","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s11999-015-4268-z","article-title":"Are changes in composition in response to treatment of a mouse model of osteogenesis imperfecta sex-dependent","volume":"473","author":"Boskey","year":"2015","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"2024021014324990900_jbmr3421-bib-0033","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014324990900_jbmr3421-bib-0034","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024021014324990900_jbmr3421-bib-0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"9419","key":"2024021014324990900_jbmr3421-bib-0036","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"2024021014324990900_jbmr3421-bib-0037","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024021014324990900_jbmr3421-bib-0038","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"2024021014324990900_jbmr3421-bib-0039","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1359\/JBMR.040126","article-title":"Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib","volume":"19","author":"Komatsubara","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024021014324990900_jbmr3421-bib-0040","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jbmr.2486","article-title":"Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment","volume":"30","author":"Anam","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024021014324990900_jbmr3421-bib-0041","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"the effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024021014324990900_jbmr3421-bib-0042","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"2024021014324990900_jbmr3421-bib-0043","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"issue":"4","key":"2024021014324990900_jbmr3421-bib-0044","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s12098-017-2316-2","article-title":"Characteristic bands manifesting as zebra lines on radiographs in osteogenesis imperfecta","volume":"84","author":"Ishizuka","year":"2017","journal-title":"Indian J Pediatr"},{"issue":"16","key":"2024021014324990900_jbmr3421-bib-0045","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2024021014324990900_jbmr3421-bib-0046","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1601-0825.2010.01772.x","article-title":"Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate","volume":"17","author":"Wen","year":"2011","journal-title":"Oral Dis"},{"key":"2024021014324990900_jbmr3421-bib-0047","first-page":"727510","article-title":"Radiographic and MR imaging findings of the spine after bisphosphonate treatment, in a child with idiopathic juvenile osteoporosis","volume":"2015","author":"Papakonstantinou","year":"2015","journal-title":"Case Rep Radiol"},{"issue":"5","key":"2024021014324990900_jbmr3421-bib-0048","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.pmrj.2013.10.009","article-title":"Bisphosphonate treatment for children with disabling conditions","volume":"6","author":"Boyce","year":"2014","journal-title":"PM R"},{"issue":"9","key":"2024021014324990900_jbmr3421-bib-0049","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"issue":"2","key":"2024021014324990900_jbmr3421-bib-0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/PRM-140281","article-title":"Bisphosphonate use in children with pediatric osteoporosis and other bone conditions","volume":"7","author":"Szalay","year":"2014","journal-title":"J Pediatr Rehabil Med"},{"issue":"Suppl 2","key":"2024021014324990900_jbmr3421-bib-0051","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","article-title":"Experience with bisphosphonates in osteogenesis imperfecta","volume":"119","author":"Glorieux","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"2024021014324990900_jbmr3421-bib-0052","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/8756-3282(91)90044-J","article-title":"Biologically meaningful determinants of the in vitro strength of lumbar vertebrae","volume":"12","author":"Vesterby","year":"1991","journal-title":"Bone"},{"issue":"4","key":"2024021014324990900_jbmr3421-bib-0053","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jbmr.264","article-title":"Determinants of the mechanical behavior of human lumbar vertebrae after simulated mild fracture","volume":"26","author":"Wegrzyn","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014324990900_jbmr3421-bib-0054","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1359\/jbmr.1997.12.1.89","article-title":"The thickness of human vertebral cortical bone and its changes in aging and osteoporosis: a histomorphometric analysis of the complete spinal column from thirty-seven autopsy specimens","volume":"12","author":"Ritzel","year":"1997","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/7\/1272\/56649967\/jbmr3421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/7\/1272\/56649967\/jbmr3421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:01:31Z","timestamp":1710342091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/7\/1272-1282\/7605263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,3,15]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3421","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"2017-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}